| Heidi Youtsler, MSOT | |
|
9902 Windisch Rd, West Chester, OH 45069-3804 | |
| (513) 755-6600 | |
| (513) 755-3762 |
| Full Name | Heidi Youtsler |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Pediatrics |
| Location | 9902 Windisch Rd, West Chester, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043496805 | NPI | - | NPPES |
| 2187155 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | OT003351 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Heidi Youtsler, MSOT 9902 Windisch Rd, West Chester, OH 45069-3804 Ph: (513) 755-6600 | Heidi Youtsler, MSOT 9902 Windisch Rd, West Chester, OH 45069-3804 Ph: (513) 755-6600 |
News Archive
Mitochondria, tiny structures within each cell that regulate metabolism and energy use, may be a promising new target for cancer therapy, according to a new study. Manipulation of two biochemical signals that regulate the numbers of mitochondria in cells could shrink human lung cancers transplanted into mice, a team of Chicago researchers report in the journal FASEB.
Scientists working with Professor Dr. Dr. Perikles Simon, head of the Sports Medicine division of Johannes Gutenberg University Mainz (JGU) in Germany, suggest in the light of recent analyses that German children gain weight soon after entering elementary school.
Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.
HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.
› Verified 4 days ago
Sabella Smith, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7591 Tylers Place Blvd, West Chester, OH 45069 Phone: 513-755-6600 Fax: 513-755-3762 | |
Kaitlin Nishida, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7591 Tylers Place Blvd, West Chester, OH 45069 Phone: 513-755-6600 | |
Anna Brock, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7591 Tylers Place Blvd, West Chester, OH 45069 Phone: 513-755-6600 | |
Sandra E. Carlson, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9902 Windisch Rd, West Chester, OH 45069 Phone: 513-755-6600 Fax: 513-755-3762 | |
Lindsey Brinkman, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7591 Tylers Place Blvd, West Chester, OH 45069 Phone: 513-755-6600 | |
Lauren Robinson, OTA Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7591 Tyler's Place Blvrd, West Chester, OH 45069 Phone: 513-755-6600 Fax: 513-755-3762 |